BiomX Inc.

BiomX Inc. is a clinical-stage biopharmaceutical company focused on developing innovative phage-based therapies to target and destroy harmful bacteria associated with chronic diseases. The company's mission is to address significant unmet medical needs by leveraging its proprietary BacteriOphage Lead to Treatment (BOLT) platform to customize phage compositions against validated bacterial targets. Headquartered in Gaithersburg, MD, BiomX operates within the biotechnology sector, with its shares publicly traded on the NYSE American exchange.

BiomX's product pipeline has historically concentrated on phage-based therapies, including fixed cocktail and personalized treatments. Key product candidates have included BX011, a fixed multi-phage cocktail in Phase 2a development for diabetic foot infections, and BX211, a phage therapy that showed positive Phase 2 results for diabetic foot osteomyelitis. The company also previously developed BX004 for cystic fibrosis, which was discontinued. Beyond therapeutics, BiomX utilizes its XMarker platform for metagenomics-based biomarker discovery, notably in collaboration with Janssen and Boehringer Ingelheim for inflammatory bowel disease.

In recent developments, BiomX has undergone significant strategic shifts. In March 2026, Michael Oster was appointed Chief Executive Officer, succeeding Jonathan Solomon, with David Rokach named Chief Financial Officer. The company has initiated a strategic and financial reset, exploring a repositioning towards defense-related applications. This pivot includes the launch of X Security & Defense LTD., a new wholly-owned subsidiary, and the acquisition of Zorronet and DFSL to expand its defense and security portfolio. These moves follow the discontinuation of the BX004 trial and the commencement of insolvency proceedings for its Israeli subsidiary, BiomX Ltd., in late 2025.